Kolon Life Science Inc (102940) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Kolon Life Science Inc KRW 37,129, price KRW 13,920, upside +166.7%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Kolon Life Science Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 13,300 KRW – 70,800 KRW · fair‑value band 26,432 KRW – 46,411 KRW · the 13,920 KRW price screens below the 37,129 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Kolon Life Science in your weekly email
Every Wednesday you see whether Kolon Life Science is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain.
Show more
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for anti-cancer and intermediates; and pyrithione antimicrobial for shampoo and soap bars, cosmetic and wet wipes, fabric softeners, metalworking fluids, antifouling paints, and fire-fighters. In addition, it offers Kolon BESFLOC polymer used in chemical, food, leather, pharmaceutical, textile, and dairy industries, as well as in settling reservoirs, sludge thickeners, floating reservoirs, and dehydrators in sewage treatment plants. The company was formerly known as Korea Tissuegene Asia, Ltd. and changed its name to Kolon Life Science Inc. in January 2006. Kolon Life Science Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Stock analysis
Kolon Life Science Inc (102940) currently trades at 13,920 KRW, while our model-based Fair Value estimate is 37,129 KRW, implying the stock looks roughly 62.5% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 37,760 KRW per share, and 12 of the 14 models we run sit above the 13,920 KRW price.
Bear case: the Economic Profit group reads lowest at 9,839 KRW, and 2 of the 14 models stay below the price. Evidence for this calculation is low.
Scenario range: 26,432 KRW (bear) to 46,411 KRW (bull), the price of 13,920 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Kolon Life Science Inc reported revenue of 209B KRW in FY2025 versus 165B KRW in FY2021, a compound +6.0%/yr. Reported net income was 25.0B KRW in FY2025.
Key figures
Market cap 422B KRW (≈ $296M) · P/S ratio 2.21 · Net margin 11.9% · Return on equity −3,386% · Return on assets (EBIT) −4.3% · Operating margin 0.7% · Revenue (TTM) 191B KRW · Revenue growth (YoY) +20.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 80% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −41% fair-value upside, at 167%, 102940 screens cheaper than that median.
Fair Value models
Bear 26,432 KRWFair Value 37,129 KRWBull 46,411 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.43/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+29.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Start year 2020 (pandemic). Over 10 years: +5.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 56 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Kolon Life Science Inc Fair Value". https://www.fairvalue-calculator.com/stock/102940
Frequently asked questions
Is Kolon Life Science Inc (102940) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 37,129 KRW versus a price of 13,920 KRW, about +167% upside (undervalued).
What is the fair value of 102940?
Our model-based fair value for Kolon Life Science Inc is 37,129 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 13,920 KRW.
What is the quality score of 102940?
Kolon Life Science Inc has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kolon Life Science Inc (102940)?
Our model-based price target is the fair value of 37,129 KRW (as of Sep 24, 2026) from 14 valuation models. Cautious scenario 26,432 KRW, optimistic scenario 46,411 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Kolon Life Science Inc stock forecast for 2026?
Our models put fair value at 37,129 KRW, about +167% upside versus a price of 13,920 KRW (undervalued). Cautious scenario 26,432 KRW, optimistic scenario 46,411 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Kolon Life Science Inc (102940)?
Kolon Life Science Inc reported trailing-twelve-month revenue of about 191B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Kolon Life Science Inc (102940)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kolon Life Science Inc it is 37,129 KRW per share (as of Sep 24, 2026), against a price of 13,920 KRW. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Kolon Life Science Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 102940 trades below its calculated fair value: price 13,920 KRW, fair value 37,129 KRW, a gap of about +167% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 102940?
No. The price is what the market pays today (13,920 KRW); the fair value is what the company's own numbers justify (37,129 KRW). For Kolon Life Science Inc the two are 23,209 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Kolon Life Science Inc worth?
The market values Kolon Life Science Inc at about 422B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 13,920 KRW; our models calculate a fair value of 37,129 KRW per share.
What do the bullish and bearish scenarios say about 102940?
Our models span a range for Kolon Life Science Inc: cautious scenario 26,432 KRW, base 37,129 KRW, optimistic 46,411 KRW per share (as of Sep 24, 2026, price 13,920 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kolon Life Science Inc (102940)?
Balance-sheet figures for Kolon Life Science Inc (as of Sep 24, 2026): debt of 0.01 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is 102940 from its 52-week high?
Kolon Life Science Inc trades at 13,920 KRW, about 80% below its 52-week high of 70,800 KRW and 5% above the low of 13,300 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 37,129 KRW is for.
Which stocks are comparable to Kolon Life Science Inc?
From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kolon Life Science Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 13,920 KRW, calculated fair value 37,129 KRW (+167%), Quality Score 33/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 102940 calculated?
We run Kolon Life Science Inc through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 37,129 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Kolon Life Science Inc currently trades 167 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kolon Life Science Inc (102940)?
The closing price on Sep 23, 2026 was 13,920 KRW. Our model-based fair value is 37,129 KRW, about +167% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kolon Life Science Inc right now?
The large discount to fair value meets weak quality (33/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (26,432 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Kolon Life Science Inc
How large is the market capitalisation of Kolon Life Science Inc (102940)?
The market capitalisation of Kolon Life Science Inc is 422B KRW (≈ $296M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kolon Life Science Inc (102940)?
The price-to-sales ratio of Kolon Life Science Inc is 2.21 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Kolon Life Science Inc (102940)?
The net margin of Kolon Life Science Inc is 11.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kolon Life Science Inc (102940)?
The return on equity (ROE) of Kolon Life Science Inc is −3,386% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kolon Life Science Inc (102940)?
On an EBIT basis the return on assets of Kolon Life Science Inc is −4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kolon Life Science Inc (102940)?
The operating margin of Kolon Life Science Inc is 0.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kolon Life Science Inc (102940)?
Revenue at Kolon Life Science Inc is growing +20.2% versus a year earlier (3y avg +9.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kolon Life Science Inc (102940)?
Earnings per share at Kolon Life Science Inc are growing −45.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Kolon Life Science Inc (102940) generate?
The free cash flow of Kolon Life Science Inc is −28.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Kolon Life Science Inc (102940) carry?
The net debt of Kolon Life Science Inc is 91.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Kolon Life Science Inc in the live analysis
One click puts Kolon Life Science Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
